ReviewCurrent pain and headache reports2015
A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine.
Review in Current pain and headache reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05646160 (Effects of Myofascial Trigger Points Therapy in Migraine.), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Myofascial Trigger Points Therapy in Migraine.
Who cites it
11 citing papers in PubMed.
- Article
- Results of a Web-Based Survey on 2105 Greek Migraine Patients-Second Part: Efficacy of Acute and Prophylactic Migraine Treatments and Corresponding Patients' Reported Satisfaction.Medicina (Kaunas, Lithuania) · 2022Article
- Vitamin D in Neurological Diseases.International journal of molecular sciences · 2022Review
- Migraine Characteristics, Comorbidities, Healthcare Resource Utilization, and Associated Costs of Early Users of Erenumab in the USA: A Retrospective Cohort Study Using Administrative Claims Data.Pain and therapy · 2021Article
- Riboflavin in Neurological Diseases: A Narrative Review.Clinical drug investigation · 2021Review
- Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.Advances in therapy · 2020Review
- Review
- A Physiological Approach to Assessment and Rehabilitation of Acute Concussion in Collegiate and Professional Athletes.Frontiers in neurology · 2018Article
- OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience.Therapeutic advances in neurological disorders · 2017Review
- Chronic Orofacial Pain: Burning Mouth Syndrome and Other Neuropathic Disorders.Journal of pain management & medicine · 2017Article
- Multi-Disciplinary Management of Athletes with Post-Concussion Syndrome: An Evolving Pathophysiological Approach.Frontiers in neurology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic migraine is a debilitating disorder that affects 2 % of the global population and imparts a significant societal and economic impact. The cornerstones of chronic migraine management include making an accurate diagnosis, patient education, treatment of comorbid conditions, and selection of an appropriate, evidence-based acute and preventive treatment regimen. Although it is common to treat chronic migraine with preventive medications effective for episodic migraine, a number of treatment options exist with specific evidence for effectiveness in chronic migraine. Currently, onabotulinumtoxinA injections are the only FDA-approved preventive treatment for chronic migraine. A number of non-medication treatment options including occipital nerve and supraorbital nerve stimulation have shown promise as effective prevention for patients either unable to tolerate or unable to obtain relief from oral medications, but more research is necessary.
Indexed as
Identifiers
26286071What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.